martes, 8 de enero de 2013

ABBOTT ahora es también AbbVie...


AbbVie, in a statement, noted that the new company “combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader.” And its product portfolio includes one of the best-selling prescription drugs, Humira, and a number of other established products, such as AndroGel, Lupron, Synthroid and Kaletra, among others. Estimated first-year sales for AbbVie is $18 billion.
AbbVie chairman and chief executive Richard Gonzalez noted that the new company is positioned well with its outstanding product portfolio, a solid pipeline and enthusiastic workforce. “With those assets and a relentless focus on innovation we intend to create significant value for our shareholders,” he said in a statement.

AbbVieSpins Off from Abbott and Debuts on the New York Stock Exchange

Ver: AbbVie Web
Publicar un comentario